HBIO

Harvard BioscienceB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$7.25

+12.2% vs current

Most likely

Base case

45%

Probability

Target price

$5.00

-22.6% vs current

B-

Bear case

30%

Probability

Target price

$2.75

-57.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-27

AI commentary

Coverage is thin and mostly limited to the Q1 earnings snapshot and recaps, with no usable analyst-revision package in the evidence packet and no social-sentiment context. The tone is mildly constructive on refinancing and margin improvement, but the peer set is not strong enough for standard conviction and the stock still needs Project Viking execution plus better balance-sheet progress; without a reliable post-print market-reaction series, confidence stays capped.

RankAlpha Sentiment Codex - 2026-05-27

Open full AI memo

Evidence flagged

Coverage is limited for this name, so the memo relies on a thinner evidence base.; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-05-12eventQ1 2026 print confirmed stabilization and covenant complianceHigh impact

Q1 2026 showed stabilization: total revenue was $20.755M, gross margin was 59.0%, and net loss narrowed to $3.424M; management also said the December 2025 refinancing alleviated the going-concern issue and that the company was compliant with minimum liquidity and adjusted EBITDA covenants. [#10-Q-2026-05-12]

2026-12-31catalystFinancing and runway proof remain the main non-operating catalystHigh impact

The balance-sheet repair story still needs proof across 2026: cash was $7.1M against $40M of borrowings, and the 2025 Loan Agreement includes minimum liquidity and adjusted EBITDA covenants plus warrant overhang. Sustained covenant compliance or another financing action would be the clearest long-horizon capital-structure catalyst. [#10-Q-2026-05-12][#10-K-2026-03-13]

2027-12-31catalystProject Viking can lower the cost base if execution stays cleanHigh impact

Project Viking remains the key long-duration self-help lever: the company expects about $3M of cost savings in 2027 and about $4M annually from 2028, but it also expects $3.4M-$4.4M of pre-tax restructuring charges and a Holliston manufacturing exit. [#10-K-2026-03-13][#10-Q-2026-05-12]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-27 • Updated nightlySource: Internal modelMethodology